An open-label, dose-escalation, dose-expansion Phase 1 study to evaluate the tolerability, safety, pharmacokinetics/pharmacodynamics, and antitumor effect of ASCA101 in patients with advanced solid tumors
An Open-label, Dose-escalation, Dose-expansion, Phase 1 Study to Evaluate the Tolerability, Safety, Pharmacokinetics/Pharmacodynamics, and Antitumor Effect of ASCA101 in Patients With Advanced Solid Tumors
This is a prospective, open-label, dose escalation Phase 1 study. The purpose of this study is to evaluate the following objectives in patients with advanced solid tumors after failure of standard of care.
100 项与 ASCA-101 相关的专利(医药)